Articles | Open Access | https://doi.org/10.37547/ajbspi/Volume05Issue01-07

Dynamics of immuno-inflammatory markers in patients with chronic heart failure after myocardial infarction during treatment with rosuvastatin

M.M. Abdurakhmanov , Bukhara State Medical Institute, Karakul College of Public Health named Abu Ali ibn Sino, Bukhara, Uzbekistan
A.N. Khamraev , Bukhara State Medical Institute, Karakul College of Public Health named Abu Ali ibn Sino, Bukhara, Uzbekistan
M.S. Radjabova , Bukhara State Medical Institute, Karakul College of Public Health named Abu Ali ibn Sino, Bukhara, Uzbekistan

Abstract

In the occurrence and progression of chronic heart failure (CHF), the role of pro- inflammatory cytokines has been established: tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), which induce the synthesis of C-reactive protein (CRP), an increasing the level of these markers leads to the progression of CHF. It was determined that with the development of the maladaptive phase of left ventricular remodeling, there is a sharp rise in the level of pro- inflammatory cytokines and serum CRP, which are closely interrelated with the structural and functional changes of the left ventricle in CHF. Against the background of taking rosuvastatin at a daily dose of 20 mg, there is a decrease in the levels of pro-inflammatory cytokines and serum CRP and a positive dynamics of heart remodeling indicators.

Keywords

Systemic inflammation, left ventricular remodeling, rosuvastatin

References

Berezikova Ye.N., Shilova S.N., Yefremov

A.V. i dr. Rol' tsitokinovoy agressii v razvitii khronicheskoy serdechnoy nedostatochnosti // Kubanskiy nauchnyy meditsinskiy vestnik. – 2011. – T. 127. № 4. –

S. 29–31. (In Russian)

2.Bochenina YU.A., Kuznetsov G.E., Tenchurina L.R. Vliyaniye rozuvastatina na strukturno-funktsional'noye sostoyaniye endoteliya u bol'nykh khronicheskoy serdechnoy nedostatochnost'yu ishemicheskoy etiologii // Farmateka. – 2012. – № 17. – S. 47–51. (In Russian)

Drapkina O. M., Kontsevaya A. V.1, Kravchenko A. YA.2, Budnevskiy A. V., Tokmachev R. Ye., Chernik T. A. Biomarkery ST2 i interleykin 33 v otsenke kardial'nogo vospaleniya, fibroza i prognoza patsiyentov s khronicheskoy serdechnoy nedostatochnost'yu Rossiyskiy kardiologicheskiy zhurnal 2021;26(S3):4530 (In Russian)

Yefremov A.V. i dr. Vliyaniye faktora nekroza opukholi al'fa i polimorfnykh variantov yego gena na razvitiye i kharakter techeniya khronicheskoy serdechnoy nedostatochnosti. // Sibirskoye meditsinskoye obozreniye: yezhekvartal'nyy meditsinskiy zhurnal. – 2010. – № 4. – S. 29–31. (In Russian)

Kruchinkina Ye. V., Ryabov V. V Immunnyy otvet pri dekompensatsii ishemicheskoy serdechnoy nedostatochnosti. Rossiyskiy kardiologicheskiy zhurnal 2018; 1 (153): 72-

(In Russian)

Sazhina Ye.YU., I.V. Kozlova. Urovni tsitokinov i S-reaktivnogo belka kak kriteriy effektivnosti lecheniya bol'nykh ishemicheskoy bolezn'yu serdtsa, oslozhnennoy khronicheskoy serdechnoy nedostatochnost'yu // Kardiovask. terapiya i profilaktika. – 2008. – T. № 3. – S. 51–5. (In Russian)

Tokmachev R. Ye., Budnevskiy A. V., Kravchenko A. YA. Rol vospaleniya v patogeneze khronicheskoy serdechnoy nedostatochnosti. Terapevticheskiy Arkhiv. 2016;88(9):106-10.

doi:10.17116/terarkh2016889106-110. (In Russian)

Grilo GA, Shaver PR, Castro Bra´s LE. Mechanisms of cardioprotection via modulation of the immune response. Current Opinion in Pharmacology 2017, 33: 6-11. DOI: 10.1016/j. coph.2017.03.002.

Kosar F. Relationship between cytokines and tumour markers in patients with chronic heart failure // Eur. J. Heart Fail. - 2008. - №3. - P. 270-274.

1Taniguchi K., Kavamoto T., Kuki S., et al. Left ventricular miokardial remodeling and contractile state in chronic aortic regurgitation // Clin. Cardiol. – 2000. – Vol.23. – P. 608–14.

Article Statistics

Copyright License

Download Citations

How to Cite

M.M. Abdurakhmanov, A.N. Khamraev, & M.S. Radjabova. (2025). Dynamics of immuno-inflammatory markers in patients with chronic heart failure after myocardial infarction during treatment with rosuvastatin. American Journal Of Biomedical Science & Pharmaceutical Innovation, 5(01), 28–31. https://doi.org/10.37547/ajbspi/Volume05Issue01-07